Brii Biosciences Limited (2137.HK)

HKD 0.85

(0.0%)

Market Cap (In HKD)

621.59 Million

Revenue (In HKD)

617 Thousand

Net Income (In HKD)

-174.82 Million

Avg. Volume

682.54 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.8-2.39
PE
-
EPS
-
Beta Value
1.495
ISIN
KYG1645A1094
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhi Hong Ph.D.
Employee Count
-
Website
https://www.briibio.com
Ipo Date
2021-07-13
Details
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.